Generic

Five things for pharma marketers to know: Tuesday, November 25

Five things for pharma marketers to know: Tuesday, November 25

By By

AstraZeneca and Ranbaxy pay-for-delay case marches on; FDA extends Novartis multiple myeloma Priority Review timeline; Endo pays $25 for testosterone nasal gel.

FDA delays rule on generic drug labeling amid controversy

As generic drug use soars, the agency intends to "create parity" in label-change rules for brands and generics.

Five things for pharma marketers to know: Tuesday, November 18

Five things for pharma marketers to know: Tuesday, November 18

By By

Ackman walks away with $2.5 billion, despite no Allergan deal; Ranbaxy sues FDA over generic Nexium rights; Indian government's Health Ministry recommends breaking BMS cancer drug patent.

Five things for pharma marketers to know: Friday, November 14

Five things for pharma marketers to know: Friday, November 14

By By

Pfizer reportedly not interested in acquiring AZ; high deductible plans set to envelop healthcare insurance exchanges; GSK's mature drug portfolio finds a wholesale suitor.

Lawmakers float generic drug legislation

The bill proposes fining branded drugmakers for not complying.

Missing generic hurts Rite Aid

The drugstore chain has lowered its forecast, and generics are just one reason.

FDA sanctions don't kill a business

Bloomberg reports that India's Wockhardt has become an M&A target.

Abbott pairs generics with tax benefit

Abbott and Mylan are setting up a generics business. The all-stock deal will give some branded generics a new home and offer Abbott a tax benefit that will increase over time.

Court won't stall generic Copaxone

Court won't stall generic Copaxone

By

The Supreme Court denied Teva's request to keep branded Copaxone off the market while the appeals process shakes out.

GSK accused of wrongdoing in Poland, Wellbutrin generic revoked

Poland joins the list of countries in which GlaxoSmithKline is accused of misconduct. Meanwhile, bioequivalence issues have prompted the FDA to revoke its approval of GSK's Wellbutrin generic.

Color keeps GSK generic off the market

Color keeps GSK generic off the market

By

GlaxoSmithKline claims that Sandoz needs to change the packaging for its generic Advair.

FDA slammed over generics

Critics say the FDA is not doing enough to ensure generics quality and that communications between industry and the regulator need to improve.

Ranbaxy, Teva settle with New York State

The drugmakers admitted no wrongdoing, but are paying the state $300,000 over an agreement not to challenge generics filings.

Merck latest rival in race to copy Lantus

Merck latest rival in race to copy Lantus

By

Merck announced this week that its insulin glargine biosimilar, being developed with Samsung and Biogen Idec, would soon enter Phase-III trials.

Biogen CEO cautions on Tecfidera EU launch

Biogen CEO cautions on Tecfidera EU launch

By

The MS pill saw rapid uptake in the US last year, but its overseas launch won't be as quick, CEO George Scangos conceded this week at an analyst conference.

Teva, Pfizer settle on Viagra generic date

Teva said a settlement will allow it to sell a copy of the blockbuster ED pill prior to the official LOE.

Osbourne joins Teva for "You Don't Know Jack About MS"

Osbourne joins Teva for "You Don't Know Jack About MS"

By

Famous from his reality show, "The Osbournes," Jack narrates his life with MS in a web documentary series.

Teva unclear on 2014 future

The company released two financial scenarios. The key is generic Copaxone.

Teva denies rumors of CEO-board friction

Generic giant Teva refuted allegations that the CEO, Jeremy Levin, and the board of directors were at odds over the company's cost-saving maneuvers.

Study shows swift move from brand to generic drugs

Study shows swift move from brand to generic drugs

By

Researchers say it's not just payers supporting the switch, and all ages appear to be brand agnostic.

FDA boots Wellbutrin generic

The agency says the copycat antidepressant failed to meet bioequivalency requirements.

Teva trimming 10% of staff ahead of MS drug expiry

Teva trimming 10% of staff ahead of MS drug expiry

By

The generics giant said it will lay off about 5,000 employees as it braces for the expiry of one of its specialty brands.

Business briefs: Allergan, Incyte, Medtronic, Aetna

Allergan asks FDA to reconsider Restatis generics requirements, Incyte's Jakafi could be pancreatic cancer nemesis, Medtronic says its strategy is at the heart of where healthcare is going and Aetna's app alliance makes health local and personal.

Business briefs: Medtronic, Novo Nordisk, plus OIG's latest probe

Medtronic buys up Cardiocom, Novo will file liraglutide to battle obesity, HHS navigates cutback and looks into anti-psychotic prescription rates, Amgen's Neulasta to compete against Teva's Lonquex.

AstraZeneca, Sanofi close disappointing quarter

By

The positive way to frame the companies' quarterly results: "less bad," as generics continued to plague their balance sheets.

BMS to put more sales oomph behind Eliquis, diabetes

BMS to put more sales oomph behind Eliquis, diabetes

By

Sales slid 9% during the second quarter, with generic Avapro and Plavix inflicting financial pain. The company says it is going to invest more to promote Eliquis among HCPs and plans on deploying a wider diabetes sales force.

Business briefs: Teva, AbbVie, Novartis, Wockhardt

FDA grants Teva three years exclusivity to sell Plan B OTC for all ages; FDA gives Humira a thumbs-down for spondyloarthritis; a UK vaccine committee rejects Novartis' meningitis B shot; and Wockhardt gets a warning letter from FDA for its manufacturing practices at an Indian plant.

Actavis gets go-ahead to expand generic painkiller portfolio

By

The drug maker can now add five new doses to its generic Opana ER offerings.

Business briefs: Amgen and Wockhardt

Amgen pays $50 million for a cardio collaboration, and Wockhardt gets locked out of the EU.

Business briefs: Lilly, Novartis, Activartis, plus policy news

Eli Lilly and Boehringer Ingelheim submit a glargine biosimilar to the EMA; Novartis pipeline claims an Enbrel-superior treatment; Activartis med gets orphan drug status; generics makers may have to pay more attention to labels; Administration tweaks healthcare reform implementation over the long weekend.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters